Previous studies have indicated that ATF3 can upregulate DR5 expression in the context of anti-cancer agents camptothecin (CPT), celecoxib and zerumbone, as well as environmental carcinogen tetrachlorobenzoquinone (TCBQ) [20,21,22]. The gene discussed is ATF3; the disease is cancer.